Related Experiment Video

Updated: Sep 27, 2025

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

8.8K

EGFR signaling pathway as therapeutic target in human cancers

Elena Levantini1, Giorgia Maroni2, Marzia Del Re3

  • 1Harvard Stem Cell Institute, Harvard Medical School, Boston, MA, USA; Institute of Biomedical Technologies, National Research Council (CNR), Area della Ricerca di Pisa, Pisa, Italy.

Seminars in Cancer Biology
|April 15, 2022
PubMed

Insights

Epidermal Growth Factor Receptor (EGFR) drives cancer when altered. Research explores EGFR

Area of Science:

  • Oncology and Molecular Biology
  • Cancer Research
  • Precision Medicine

Background:

  • Epidermal Growth Factor Receptor (EGFR) is crucial for epithelial tissue maintenance.
  • Dysregulated EGFR signaling drives epithelial transformation and is implicated in numerous cancers.
  • EGFR-targeted therapies have revolutionized precision oncology.

Purpose of the Study:

  • To review key discoveries in understanding EGFR function in solid malignancies.
  • To highlight advancements in EGFR-targeted therapies, particularly in non-small cell lung cancer (NSCLC).
  • To explore novel strategies for inhibiting tumor growth and metastasis.

Main Methods:

  • Preclinical models including cell lines, organoids, and murine models.
  • Validation in clinical specimens.
  • Review of established and emerging EGFR-related oncogenic pathways and resistance mechanisms.

Main Results:

  • Identification of various mechanisms by which tumor cells dysregulate EGFR.
  • Elucidation of EGFR-related oncogenic pathways and resistance mechanisms.
  • Discovery of novel therapeutic avenues targeting tumor growth and metastatic spread.

Conclusions:

  • EGFR is a critical target in cancer therapy, especially in NSCLC adenocarcinoma.
  • Continued research into EGFR function and resistance mechanisms is vital for improving treatment outcomes.
  • Advancements in understanding EGFR have significantly expanded the therapeutic arsenal against solid tumors.
Keywords:
EGFREGFR-TKINSCLCPersonalized therapyTherapy resistance

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K